Results 1 to 10 of about 129,949 (299)
Patritumab deruxtecan induces immunogenic cell death [PDF]
OncoImmunologyAntibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic payload to cancer cells. Here, we characterized the mode of action of the ADC patritumab deruxtecan, which is a monoclonal antibody specific for Erb-B2 Receptor Tyrosine Kinase 3 ...
Sabrina Forveille +9 more
doaj +3 more sources
Immunogenic Cell Death-Based Cancer Vaccines [PDF]
Frontiers in Immunology, 2021 Cancer immunotherapy has achieved great advancement in the past decades. Whereas, its response is largely limited in immunologically cold tumors, in an urgent need to be solve.
Ming-Zhu Jin, Xi-Peng Wang
doaj +3 more sources
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death [PDF]
Cells, 2021 Radiation therapy (RT) can induce an immunogenic variant of regulated cell death that can initiate clinically relevant tumor-targeting immune responses.
Rianne D. W. Vaes +3 more
doaj +3 more sources
Datopotamab deruxtecan induces hallmarks of immunogenic cell death [PDF]
Cell StressAntibody-drug conjugates (ADCs) offer a strategy for targeted delivery of cytotoxic agents to cancer cells. In this study, we investigated the mechanism of action of datopotamab deruxtecan, an ADC composed of a monoclonal antibody targeting tumor ...
Sabrina Forveille +4 more
doaj +2 more sources
FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death [PDF]
Cell Death and DiseaseReceptor-interacting serine/threonine kinase 1 (RIPK1) is a pivotal protein controlling cell death and inflammation. RIPK1 is an attractive therapeutic target, given that the inhibition of RIPK1 kinase activity has been shown to be effective in animal ...
Byeong-Ju Kim +13 more
doaj +2 more sources
Frontiers in Oncology, 2021 Cancer treatment has rapidly entered the age of immunotherapy, and it is becoming clear that the effective therapy of established tumors necessitates rational multi-combination immunotherapy strategies.
Kellsye P. Fabian +2 more
doaj +1 more source
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. [PDF]
PLoS ONE, 2013 Durable tumor cell eradication by chemotherapy is challenged by the development of multidrug-resistance (MDR) and the failure to induce immunogenic cell death.
Chiara Riganti +8 more
doaj +1 more source
Scientific Reports, 2023 Previous studies have shown the potential of immunogenic cell death-related modalities in myeloma. The significance of IL5RA in myeloma and immunogenic cell death remains unknown.
Cong Xu +3 more
doaj +1 more source
Ferroptosis: friend or foe in cancer immunotherapy?
OncoImmunology, 2023 Ferroptosis has gained interest due to it immunogenicity and the higher sensitivity of cancer cells to it. However, it was recently shown that ferroptosis in tumor-associated neutrophils leads to immunosuppression and negatively impacts therapy. Here, we
Robin Demuynck +3 more
doaj +1 more source
Frontiers in Oncology, 2021 Necroptosis is a form of programmed cell death (PCD) characterized by RIP3 mediated MLKL activation and increased membrane permeability via MLKL oligomerization.
Jia-long Qi +7 more
doaj +1 more source